drug-eluting stent


Also found in: Dictionary, Thesaurus, Financial, Encyclopedia, Wikipedia.

drug-eluting stent

Abbreviation: DES
A stent coated with medications that it releases into surrounding intimal cells. It is designed to keep the lumen of an artery from closing both by holding the artery open and by retarding the growth of the vascular endothelium into the stent. See: bare metal stent
See also: stent
References in periodicals archive ?
Despite the recent burst of popularity for meta-analyses within the literature, the authors praise the careful analysis of drug-eluting stents presented in this issue of the journal.
While drug-eluting stents were initially proven more effective, they later suffered a setback because studies linked them to higher long-term death rates.
All myocardial infarcts were in the territory of a drug-eluting stent in the right coronary artery.
7-8 to assess the risk of late stent thrombosis from drug-eluting stents.
Despite their higher cost, and despite recent concerns about late thrombosis, drug-eluting stents now own coronary stenting.
Brilakis said that some of the previous studies have indicated that patients receiving drug-eluting stents in saphenous vein grafts may not reduce the risk of re-narrowing and may be associated with increased risk of death.
Based on current costs for drug-eluting stents, and on their ability to cut target-vessel restenosis rates by about 80%, drug-eluting stents will save money if they're used in patients with a restenosis rate of 18% or greater, and drug-eluting stents will meet accepted definitions of cost-effectiveness (costing less than $10,000 for each repeat revascularization prevented) for all patients with a bare-metal stent restenosis rate of 12% or greater.
Table 35: Leading Players in Japanese Drug-Eluting Stent Market (2006, 2007 & 2008) - Percentage Breakdown by Revenues for Johnson & Johnson and Boston Scientific III-21 Product Introductions in the Recent Past III-22 Strategic Development III-22 Strategic Corporate Activity in the Recent Past III-23 B.
With more than 1,500 subjects, these randomized clinical trials showed that drug-eluting stents can yield a 70%-90% reduction in restenosis rates across all categories of disease and all patient variables.
Both comparisons of drug-eluting stents with brachytherapy involved stenoses in bare-metal stents, but drug-eluting coronary stents also worked for treating restenosis in drug-eluting stents in a single-center series of 77 patients, which was reported in a poster at the meeting.
The need to effectively compete with the next generation of drug-eluting stents has prompted the current market leaders--Johnson & Johnson and Boston Scientific--to acquire companies with next-generation stents in their pipelines.
But this drug-eluting stent was less successful by the angiographic measures that were collected in 89% of the first 600 patients enrolled in the study.